Recommendations to neurologists on appropriately prescribing and managing patients with relapsing-remitting multiple sclerosis using novel, oral therapies.
EP. 1: Appropriate Diagnosis and Management of RRMS
The patient symptoms that help neurologists distinguish relapsing and remitting multiple sclerosis from other forms of the disease, and recommendations regarding the best timing to initiate therapy.
EP. 2: Early Initiation of Therapy for RRMS
The rationale for early treatment initiation for patients with relapsing-remitting multiple sclerosis.
EP. 3: Treatment Planning and Shared Decision-Making in RRMS
Best practices for talking about treatment goals and options with patients who have relapsing-remitting multiple sclerosis.
EP. 4: RRMS: Introducing Oral Therapy into Clinical Practice
Considerations that affect recommendations for novel oral treatment for relapsing-remitting multiple sclerosis vs a more conventional option.
EP. 5: Oral Fumarates for RRMS
Experts discuss types of oral fumarates that are available to treat relapsing-remitting multiple sclerosis, and best practices for selecting an option based on trial data and clinical experience.
EP. 6: S1P Receptor Modulators for RRMS
What to know about using S1P receptor modulators as oral therapy for relapsing-remitting multiple sclerosis.
EP. 7: S1P Receptor Modulator Treatment Selection in RRMS
Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.
EP. 8: Pyrimidine Synthesis Inhibitors for RRMS
The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.
EP. 9: Purine Antimetabolite Therapy for RRMS
Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.
EP. 10: Novel Oral Treatment Selection in RRMS
Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.
EP. 11: Assessing Response to Novel Oral Therapies in RRMS
The types of tests used to monitor response to novel oral therapies used in relapsing-remitting multiple sclerosis.
EP. 12: RRMS: Patient Prognosis and Treatment Planning
The patient factors and other variables that impact first-line treatment decisions in relapsing-remitting multiple sclerosis.
EP. 13: Managing Patients With RRMS on Novel Oral Therapy
Key takeaways from a larger discussion surrounding the utilization of novel oral agents as therapy for patients with relapsing-remitting multiple sclerosis.
2 Clarke Drive Cranbury, NJ 08512